Debrief: what this workup supports and what it does not

This case supports a narrow set of conclusions. The short-filled tube invalidates the requested platelet-function result on its own, and the low platelet count would separately limit how an aggregation signal could be read even on a valid specimen; neither call depends on the drug regimen. If a valid specimen had been available, an ADP-agonist method would have been the correct test family for the stated question, and arachidonic-acid testing would have addressed a different question about aspirin's pathway. Neither test family, nor platelet count, nor PT/aPTT, can prove adherence, confirm absorption, or set a procedural bleeding-risk cutoff on its own.

What this case does not support is a universal testing strategy. Routine platelet-function or genetic testing is not recommended for all patients after PCI; the current consensus supports selective testing considered only for a defined clinical question, using the exact assay, indication, and local policy that apply. A laboratory reporting any of these methods has separately verified or established its performance specifications and maintains quality control across the analytical process; those are institutional obligations that sit behind every result released, not clinical claims about what a given PRU or percent-aggregation number means for one patient.

Method and local policy matter throughout. The specific instrument, cartridge, reagent lot, software version, and locally verified interval govern what a number means, and none of those specifics transfer from one laboratory or platform to another without separate verification.

Verify the specimen, name the pathway the question is actually about, choose the test family built for that pathway, and report the result as a description of that pathway's signal, not as a treatment decision.